AT A GLANCE

NASDAQ: GILD
Founded: 1987
HQ: FOSTER CITY, CA

$82.3B Market Cap
(as of 2/4/2021)

~12,000 Employees

Presence in >35 Countries across 6 Continents

3 Primary Disease Areas:

VIRAL DISEASES

INFLAMMATORY DISEASES

ONCOLOGY

4Q20 FINANCIALS

PRODUCT SALES | DILUTED NON-GAAP EPS | OPERATING CASH FLOW
$7.3B | $2.19 | $1.9B

COMMERCIAL PORTFOLIO HIGHLIGHTS

Human Immunodeficiency Virus (HIV)

Treatment

Prevention

Viral Diseases

Hepatitis C Virus (HCV)

Hepatitis B Virus (HBV)

INFLAMMATORY DISEASES

ONCOLOGY

ANALYST COVERAGE

**Viral Disease Pipeline**

**Emerging Viruses**
- Vakicyv® (remdesivir for injection)
- Remdesivir inhalin form (GS-5794)
- Lenacapavir capidal inhibitor (GS-6207)
- bNAb combination (GS-5423, GS-2872)²
- Lemiflunomide TLR-9 agonist (GS-1709)³
- Votaxolom TLR-7 agonist (GS-9420)²
- Eltopivarn bNAb (GS-9722)
- Effector IgG 42 (GS-9723)²
- Unboosted protease inhibitor (GS-1156)²
- Long acting bictegravir (GS-9883)
- Ora-LD L1 small molecule (GS-4224)

**HIV**
- Hepciclovir® (Buleveltivird)²
- Hepciclovir® (Buleveltivird) + Peg-Inf²
- Solpentolom TLR-8 agonist (GS-9868)
- Oral PD-L1 small molecule (GS-4224)

**HBV & HDV**
- HDV
- MAA Approved
- MAA Filed

**Phase 1**
- Outpatient COVID-19
- HIV LA HTE
- HIV Cure
- HIV Cure
- HIV Cure
- HIV Cure
- HIV Treatment
- HIV LA

**Phase 2**
- Phase 2
- Phase 2
- Phase 2
- Phase 2
- Phase 2
- Phase 2
- Phase 2

**Phase 3**
- Phase 3
- Phase 3
- Phase 3
- Phase 3
- Phase 3
- Phase 3
- Phase 3

**Filed**
- Filed
- Filed
- Filed
- Filed
- Filed
- Filed
- Filed

**Inflammatory Disease Pipeline**

**Inflammatory Disease**
- Filgotinib JAK-1 inhibitor (GS-6034)
- TPL2 inhibitor (GS-5290)
- IRAK4 inhibitor (GS-5718)
- Tiribrutinib BTK inhibitor (GS-4059)
- Cilofexor FXR agonist (GS-9674)
- Ziralaxet ATAX inhibitor (GLPG-1600)
- Cilofexor / firsocostat combination
- Selonsertib ASK1 inhibitor (GS-4997)

**Fibrotic Disease**
- Galapagos
- Galapagos

**Options**
- Inflammatory and Fibrois Diseases
- Multiple pre-clinical stage programs

**Oncology Pipeline**

**Cell Therapy**
- Tecartus™ (Brexu-cel)²
- Asi-cel
- Yesart© (Asi-cel)³
- Brexu-cel
- Yesart© (Asi-cel)³
- Yesart© (Asi-cel)³
- KITE-718 (MAGE-A3/A6)³
- KITE-439 (HPV-16 E7)³
- Brexu-cel

**Non-Cell Therapy**
- Trodelvy™ Sacituzumab govitecan-hylb³
- Sacituzumab govitecan-hylb (GS-0132)
- Magrolimab anti-CD47 (GS-4721)²
- Magrolimab anti-CD47 (GS-0132) + CSU³
- Magrolimab anti-CD47 (GS-4721)²
- Magrolimab anti-CD47 (GS-4721)²
- Magrolimab anti-CD47 (GS-4721)²
- P3 and Registrational P2 trials
- Oral PD-L1 small molecule inhibitor (GS-4224)
- Magrolimab anti-CD47 (GS-4721)²
- FLJ55R agonist (GS-3582)
- Anti-o-CT (GS-0174)
- Anti-SRP-a (GS-0189)

**Options**
- Arcus
- Agenus
- Tisana
- Flonox

**MAA Filed**
- MAA Filed
- MAA Filed
- MAA Filed
- MAA Filed
- MAA Filed
- MAA Filed
- MAA Filed

**Clinical Stage Programs**
- Clinical collaboration with Genentech.
- Includes collaboration with Phase 3 Collaboration with NIH.

**Clinical Stage Programs**
- Including in-licensed or acquired programs currently between phase 1 and NDA/BLA/MAA approval.

**MAA and BLA Approval**
- Includes non-Cell therapy options. Includes agreements to acquire NIV hy. Submission of transaction subject to regulatory clearances and other conditions. Conditionally approved by the EMA for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020. EV - Emerging viruses. bNAb - Broadly neutralizing antibody. TME - Tumor microenvironment. Pipeline shown above as of end of Q4'20.

**Non-Cell therapy options**
- Includes agreements to acquire MIV hy. Submission of transaction subject to regulatory clearances and other conditions. Conditionally approved by the EMA for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020. EV - Emerging viruses. bNAb - Broadly neutralizing antibody. TME - Tumor microenvironment. Pipeline shown above as of end of Q4'20.